Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision — BigGo Finance
Replimune Group Inc. (REPL) shares rose over 120% premarket after an FDA advisory panel voted 10-3 that IGNYTE trial efficacy for RP1 in advanced melanoma is evaluable and clinically meaningful. The FDA decision on the resubmitted BLA is due by Aug 2, 2026. Analysts upgraded REPL; short interest is about 28.2% of float.
How this was made
The 30-second read
Why it matters
The FDA advisory committee’s 10-3 vote that IGNYTE efficacy is evaluable and clinically meaningful is a major regulatory inflection point, but the FDA’s final decision on the BLA resubmission remains the decisive catalyst.
Market read
Traders are likely to reprice REPL aggressively on the advisory vote and then manage event risk into the Aug 2 FDA decision, with short interest and retail sentiment potentially amplifying moves.
What to watch
The article highlights single-arm IGNYTE evidence and prior FDA criticisms, so traders should weigh the confirmatory trial timeline and the possibility that FDA focuses on evidentiary rigor over panel sentiment.
Background
Replimune’s RP1 (oncolytic immunotherapy) has faced two prior FDA rejections for the IGNYTE evidence package, with a resubmission under Class 1 review.
Ticker impact
Replimune’s FDA advisory panel voted 10-3 that IGNYTE efficacy is evaluable and clinically meaningful for RP1, ahead of an Aug 2 decision.
Expect elevated volatility and momentum trading into the Aug 2 FDA decision, with potential profit-taking after the initial gap if approval odds are already priced.
The article reports a specific, time-sensitive regulatory milestone (10-3 vote) plus the upcoming FDA decision date, which directly changes approval expectations and trader positioning.
Market effects
Positive read-through for oncolytic immunotherapy and post-anti-PD-1 melanoma programs, potentially improving sentiment toward similar late-stage biotech assets.
Limited direct regional spillover; primary impact is on US-listed biotech risk appetite.
Moderate, as FDA regulatory outcomes can influence global biotech valuation multiples for comparable immuno-oncology approaches.
Counterpoint
A favorable advisory vote is not approval; FDA can still issue another Complete Response Letter, especially given prior rejections and staff concerns about trial design.
Key entities
- companyReplimune Group Inc.
Subject of the article; RP1 melanoma therapy is under FDA review with an Aug 2 decision date.
- productRP1
Investigational oncolytic immunotherapy used with nivolumab in the IGNYTE trial.
- clinical_programIGNYTE trial
Single-arm study whose efficacy interpretability was evaluated by the FDA advisory committee.
- regulatorFDA Cellular, Tissue, and Gene Therapies Advisory Committee
Voted 10-3 that IGNYTE efficacy results are evaluable and clinically meaningful.
- companyBristol Myers Squibb Co.
Supplies nivolumab (Opdivo), used in combination with RP1 in IGNYTE.
